AU · rank #1 · 2026-09-07
SNT
GPW · PLN · $761M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.997 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$2.35 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $373.00 | +12.6% |
| Momentum acceleration 3-month minus 12-month momentum. | +6.75% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | — |
| Gross margin TTM | +23.5% |
| 52w high | $398.40 |
| Market cap (USD) | $761M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik is a Polish integrated healthcare company combining radiopharmaceutical manufacturing, medical imaging equipment distribution, and proprietary medical IT software serving oncology, cardiology, and neurology markets.
Rationale
100% analyst revision agreement, a 2.35 EPS revision over 30 days, and 90-day revenue nearly doubling to PLN 733M confirm the upside signal is anchored in genuine, accelerating fundamental delivery rather than sentiment drift.
Material risks
- 1With only 3 analysts covering SNT and target price dispersion of 25.7%, the analyst upside signal rests on a thin, potentially stale consensus that could reprice sharply on any single estimate change or liquidity event.
- 2Revenue visibility is tied to lumpy equipment sales cycles and Polish public healthcare capex rather than long-term contracts, meaning the strong Q3 growth rate may not sustain if hospital procurement budgets tighten post-2026.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.